Programmed Death Ligand 1 (PD-L1) expression in primary Angiosarcoma

Research output: Contribution to journalArticlepeer-review


Angiosarcomas are rare malignant endothelial-cell tumors of vascular or lymphatic origin, and are among the most aggressive subtypes of soft-tissue sarcomas. The prognosis is poor and treatment is challenging in many cases. PD-1/PD-L1 pathway plays a critical role in immune escape of tumor cells. Recent studies described that PD-L1 is widely expressed in various types of cancer, providing the basis for the development of PD1/PD-L1 antibodies as anti-cancer immunotherapy. Despite the well-known potential of PD-L1 as prognostic and predictive biomarker, only few studies described its IHC expression in cancer subtypes for the extreme difficulty in developing standard protocol with the different antibody clones available. We analyzed the IHC expression of PD-L1 on a series of angiosarcomas at different body location, showing its aberrant expression in about 66% of samples with no relation with prognosis. Our study allowed us to correctly define PD-L1 staining in angiosarcoma tumor tissues with final purpose to stratify patients for immune checkpoint inhibitors therapies.

Original languageEnglish
Article number19060
Pages (from-to)3166-3172
Number of pages7
JournalJournal of Cancer
Issue number16
Publication statusPublished - 2017


  • Angiosarcoma
  • IHC evaluation
  • PD-L1

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Programmed Death Ligand 1 (PD-L1) expression in primary Angiosarcoma'. Together they form a unique fingerprint.

Cite this